EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS FROM CHINA, BRAZIL, AND SOUTH KOREA WITH RHEUMATOID ARTHRITIS WHO HAVE HAD INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS

被引：2
|
作者：
Zeng, X. [1 ,2 ]
Zhao, D. [3 ]
Radominski, S. [4 ]
Keiserman, M. [5 ]
Lee, C. K. [6 ]
Meerwein, S. [7 ]
Enejosa, J. [8 ]
Sui, Y. [8 ]
Mohamed, M. E. [8 ]
Park, W. [9 ]
机构：
[1] Chinese Acad Med Sci, Dept Rheumatol, Peking Union Med Coll Hosp PUMCH, Beijing, Peoples R China
[2] Natl Clin Res Ctr Dermatol & Immunol Dis NCRC DID, Beijing, Peoples R China
[3] Shanghai Changhai Hosp, Shanghai, Peoples R China
[4] Univ Fed Parana, Curitiba, Parana, Brazil
[5] Pontifical Catholic Univ, Porto Alegre, RS, Brazil
[6] Asan Med Ctr, Seoul, South Korea
[7] AbbVie Deutschland GmbH & Co KG, Pharmaceut Dev, Ludwigshafen, Germany
[8] AbbVie Inc, N Chicago, IL USA
[9] Inha Univ Hosp, Incheon, South Korea
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.1521
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0160
引用
收藏
页码：1016 / 1017
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Upadacitinib in Patients from China, Brazil, and South Korea with Rheumatoid Arthritis Who Have Had Inadequate Response to Conventional Synthetic Disease-modifying Antirheumatic Drugs
    Zeng, Xiaofeng
    Zhao, Dongbao
    Radominski, Sebastiao
    Keiserman, Mauro
    Lee, Chang Keun
    Meerwein, Sebastian
    Enejosa, Jeffrey
    Sui, Yunxia
    Mohamed, Mohamed-Eslam
    Park, Won
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [2] EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS FROM CHINA BRAZIL, AND SOUTH KOREA WITH RHEUMATOID ARTHRITIS WHO HAVE HAD INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING NTIRHEUMATIC DRUGS
    Zeng, Xiaofeng
    Zhao, Dong-Boa
    Radominski, Sebastian
    Keiserman, Mriuro
    Lee, Chang Keun
    Meerwein, Sebastian
    Enejosa, Jeffery
    Sui, Yunxia
    Mohamed, Mohamed-Eslam
    Park, Won
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 98 - 99
  • [3] LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS FROM CHINA, BRAZIL, AND SOUTH KOREA WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: RESULTS AT 64 WEEKS
    Zeng, X.
    Zhao, D.
    Radominski, S.
    Keiserman, M.
    Lee, C. K.
    Martin, N.
    Meerwein, S.
    Sui, Y.
    Park, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1156 - 1157
  • [4] Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)
    Burmester, Gerd R.
    van den Bosch, Filip
    Tesser, John
    Shmagel, Anna
    Liu, Yanxi
    Khan, Nasser
    Camp, Heidi S.
    Kivitz, Alan
    JOURNAL OF RHEUMATOLOGY, 2024, 51 (07) : 663 - 672
  • [5] EFFICACY AND SAFETY OF UPADACITINIB IN A CHINESE SUBGROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Zeng, X.
    Liu, Y.
    Hu, J.
    Li, J.
    Wang, Y.
    Zhao, D.
    Wu, L.
    Xiao, Z.
    Li, Z.
    Xu, J.
    Meerwein, S.
    Xie, Y.
    Liang, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1324 - 1324
  • [6] LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS FROM CHINA, BRAZIL, AND SOUTH KOREA WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE -MODIFYING ANTIRHEUNLVEIC DRUGS: RESULTS NE 64 WEEKS
    Zeng, Xiaofeng
    Zhao, Dongbao
    Radominski, Sebastiao
    Keiserman, Mauro
    Lee, Chang K.
    Martin, Naomi
    Meerwein, Sebastian
    Sui, Yunxia
    Park, Won
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S104 - S104
  • [7] Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy
    Zeng, Xiaofeng
    Zhao, Dongbao
    Radominski, Sebastiao C.
    Keiserman, Mauro
    Lee, Chang K.
    Meerwein, Sebastian
    Enejosa, Jeffrey
    Sui, Yunxia
    Mohamed, Mohamed-Eslam F.
    Park, Won
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2021, 24 (12) : 1530 - 1539
  • [8] Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
    Charles-Schoeman, Christina
    Burmester, Gerd
    Nash, Peter
    Zerbini, Cristiano A. F.
    Soma, Koshika
    Kwok, Kenneth
    Hendrikx, Thijs
    Bananis, Eustratios
    Fleischmann, Roy
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (07) : 1293 - 1301
  • [9] Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs
    Choy, Ernest
    Freemantle, Nick
    Proudfoot, Clare
    Chen, Chieh-I
    Pollissard, Laurence
    Kuznik, Andreas
    van Hoogstraten, Hubert
    Mangan, Erin
    Carita, Paulo
    Thi-Minh-Thao Huynh
    ADVANCES IN THERAPY, 2019, 36 (04) : 817 - 827
  • [10] Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs
    Ernest Choy
    Nick Freemantle
    Clare Proudfoot
    Chieh-I Chen
    Laurence Pollissard
    Andreas Kuznik
    Hubert van Hoogstraten
    Erin Mangan
    Paulo Carita
    Thi-Minh-Thao Huynh
    Advances in Therapy, 2019, 36 : 817 - 827
12345